97 related articles for article (PubMed ID: 14730476)
21. Editorial: Thrombosis prophylaxis with new anticoagulants: Routine and specific risk groups.
Kozek-Langenecker SA
Wien Med Wochenschr; 2011 Feb; 161(3-4):53. PubMed ID: 21404138
[No Abstract] [Full Text] [Related]
22. Emerging therapies in anticoagulation.
Ansell JE
Manag Care; 2004 Sep; 13(9 Suppl):8-12. PubMed ID: 15493218
[No Abstract] [Full Text] [Related]
23. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants.
Stief TW
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):265-9. PubMed ID: 17413764
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
25. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
[TBL] [Abstract][Full Text] [Related]
26. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
Martí-Fàbregas J; Mateo J
Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
[TBL] [Abstract][Full Text] [Related]
27. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
29. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
30. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Steffel J; Lüscher TF
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
[TBL] [Abstract][Full Text] [Related]
31. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.
Leitner JM; Jilma B; Mayr FB; Cardona F; Spiel AO; Firbas C; Rathgen K; Stähle H; Schühly U; Graefe-Mody EU
Clin Pharmacol Ther; 2007 Jun; 81(6):858-66. PubMed ID: 17410124
[TBL] [Abstract][Full Text] [Related]
33. Ancylostoma ceylanicum anticoagulant peptide-1: role of the predicted reactive site amino acid in mediating inhibition of coagulation factors Xa and VIIa.
Mieszczanek J; Harrison LM; Cappello M
Mol Biochem Parasitol; 2004 Sep; 137(1):151-9. PubMed ID: 15279961
[TBL] [Abstract][Full Text] [Related]
34. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
35. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
Franciskovich JB; Masters JJ; Tinsley JM; Craft TJ; Froelich LL; Gifford-Moore DS; Klimkowski VJ; Smallwood JK; Smith GF; Smith T; Towner RR; Weir LC; Wiley MR
Bioorg Med Chem Lett; 2005 Nov; 15(21):4838-41. PubMed ID: 16140530
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
Wang ZM; Li L; Li B; Guo SY
Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
Hosaka Y; Matsumoto M; Shinozaki M; Ohno T; Yatagai Y; Kamiya M; Kurokawa M; Nishida H; Matsusue T; Mizuguchi K; Ishii H
Eur J Pharmacol; 2006 Jan; 529(1-3):164-71. PubMed ID: 16316651
[TBL] [Abstract][Full Text] [Related]
38. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Turpie AG
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1238-47. PubMed ID: 17379841
[TBL] [Abstract][Full Text] [Related]
39. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
40. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
